University of Wisconsin Foundation Has $11.42 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

University of Wisconsin Foundation lowered its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 410,630 shares of the company's stock after selling 13,219 shares during the period. Akero Therapeutics makes up 8.3% of University of Wisconsin Foundation's holdings, making the stock its 6th largest position. University of Wisconsin Foundation owned approximately 0.59% of Akero Therapeutics worth $11,424,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of AKRO. FMR LLC raised its holdings in Akero Therapeutics by 732.1% during the third quarter. FMR LLC now owns 30,337 shares of the company's stock worth $870,000 after purchasing an additional 26,691 shares in the last quarter. XTX Topco Ltd bought a new position in Akero Therapeutics during the third quarter valued at about $308,000. Y Intercept Hong Kong Ltd raised its position in Akero Therapeutics by 13.8% in the third quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company's stock worth $485,000 after acquiring an additional 2,049 shares in the last quarter. Barclays PLC lifted its holdings in Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company's stock valued at $3,662,000 after acquiring an additional 71,652 shares during the last quarter. Finally, Exome Asset Management LLC bought a new position in shares of Akero Therapeutics during the 3rd quarter valued at about $2,212,000.

Insider Buying and Selling

In related news, insider Catriona Yale sold 9,073 shares of the company's stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $37.91, for a total value of $343,957.43. Following the sale, the insider now owns 95,034 shares of the company's stock, valued at $3,602,738.94. The trade was a 8.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Patrick Lamy sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total value of $285,150.00. Following the transaction, the vice president now owns 33,492 shares of the company's stock, valued at $1,910,048.76. This trade represents a 12.99 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have bought 341,309 shares of company stock valued at $15,863,578 and have sold 287,458 shares valued at $13,689,886. 7.94% of the stock is owned by company insiders.

Akero Therapeutics Stock Up 0.5 %

Shares of NASDAQ:AKRO traded up $0.19 on Friday, reaching $37.63. The company had a trading volume of 521,577 shares, compared to its average volume of 854,711. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $3.00 billion, a P/E ratio of -10.03 and a beta of -0.18. The stock has a 50-day moving average price of $43.52 and a 200 day moving average price of $36.06. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, equities analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on AKRO. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. HC Wainwright upped their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Canaccord Genuity Group boosted their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. UBS Group lifted their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.